Compositions and methods for the treatment of multiple sclerosis

Patent metadata

Field	Value
Publication number	US-9988340-B2
Application number	US-201514791492-A
Country	US
Kind code	B2
Filing date	Jul 6, 2015
Priority date	Sep 29, 2014
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

The invention relates to the compounds of formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other inflammatory diseases.

First claim

The invention claimed is:

1. A compound of Formula II:

or a pharmaceutically acceptable salt, enantiomer, or stereoisomer thereof, wherein R 1 and R 3 each independently represents:

 and
R 2 and R 4 each independently represents:

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , wherein said pharmaceutical composition is formulated to treat an underlying etiology with an effective amount by administering the pharmaceutical composition to a patient in need by oral administration, delayed release or sustained release, transmucosal, administration syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

4. Compounds and compositions of claim 3 , wherein said compounds and compositions are formulated for the treatment of multiple sclerosis and psoriasis.

Assignees

• Kandula Mahesh
• Cellix Bio Private Ltd

Inventors

• Kandula Mahesh

Classifications

• A61P37/02

  Immunomodulators · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title